{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:30:58Z","timestamp":1790656258039,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.semarthrit.2021.01.005","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T11:35:23Z","timestamp":1611747323000},"page":"347-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review"],"prefix":"10.1016","volume":"51","author":[{"given":"Robert T.","family":"Keenan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Botson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim R.","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissa","family":"Padnick-Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"LaMoreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Pillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.semarthrit.2021.01.005_bib0001","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1096\/fasebj.2.15.3192041","article-title":"Uricase protein sequences conserved during vertebrate evolution but absent in humans","volume":"2","author":"Varela-Echavarria","year":"1988","journal-title":"FASEB J"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.01.005_bib0002","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.01.005_bib0003","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs"},{"issue":"9","key":"10.1016\/j.semarthrit.2021.01.005_bib0004","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2021.01.005_bib0005","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.01.005_bib0006","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.01.005_bib0007","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.01.005_bib0008","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/RHU.0000000000000200","article-title":"Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy","volume":"20","author":"Baraf","year":"2014","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.01.005_bib0009","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.semarthrit.2021.01.005_bib0010","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/rheumatology\/ket017","article-title":"The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure","volume":"52","author":"Krintel","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.01.005_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.MIB.0000436951.80898.6d","article-title":"Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"O'Meara","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.01.005_bib0012","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apt.13994","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","volume":"45","author":"Strik","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.semarthrit.2021.01.005_bib0013","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2021.01.005_bib0014","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/annrheumdis-2014-206616","article-title":"The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study","volume":"74","author":"Lie","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.01.005_bib0015","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"Krieckaert","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.01.005_bib0016","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001047","article-title":"Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial","volume":"6","author":"Ducourau","year":"2020","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.01.005_bib0017","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.01.005_bib0018","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/jgh.12263","article-title":"Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy","volume":"28","author":"Ong","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.01.005_bib0019","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semarthrit.2018.11.006","article-title":"Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature","volume":"49","author":"Bessen","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.01.005_bib0020","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1016\/j.transproceed.2018.03.010","article-title":"A case report of immunosuppressant medication associated polyarticular tophaceous gout successfully treated using the polyethylene glycol conjugated uricase enzyme pegloticase","volume":"50","author":"Freyne","year":"2018","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.semarthrit.2021.01.005_bib0021","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.semarthrit.2016.09.007","article-title":"Pegloticase failure and a possible solution: immunosuppression to prevent intolerance and inefficacy in patients with gout","volume":"46","author":"Berhanu","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2021.01.005_bib0022","doi-asserted-by":"crossref","DOI":"10.1007\/s40744-020-00222-7","article-title":"Increased efficacy and tolerability of pegloticase in patients with uncontrolled gout co-treated with methotrexate: a retrospective study","author":"Albert","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.semarthrit.2021.01.005_bib0023","article-title":"Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR)","author":"Botson","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.01.005_bib0024","article-title":"Pretreatment and co-administration with methotrexate improved durability of pegloticase response: a prospective observational, proof-of-concept, case series","author":"Botson","year":"2020","journal-title":"J Clin Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2021.01.005_bib0025","first-page":"450","article-title":"Leflunomide co-therapy with pegloticase in uncontrolled gout [abstract]","volume":"79","author":"Masri","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2021.01.005_bib0026","first-page":"438","article-title":"Companion immunosuppression with azathioprine increases the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout [abstract]","volume":"79","author":"Rainey","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"suppl 10","key":"10.1016\/j.semarthrit.2021.01.005_bib0027","article-title":"Reducing immunogenicity of pegloticase (RECIPE) with concomitant use of mycophenolate mofetil in patients with refractory gout\u2212a phase II double blind randomized controlled trial [abstract]","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.01.005_bib0028","first-page":"238","article-title":"Concomitant immunosuppressant use with pegloticase in patients with tophaceous gout - a case series","volume":"14","author":"Bessen","year":"2019","journal-title":"Int J Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.01.005_bib0029","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3899\/jrheum.170806","article-title":"The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years","volume":"45","author":"Elfishawi","year":"2018","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.01.005_bib0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/SMJ.0000000000000082","article-title":"Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street","volume":"107","author":"Karis","year":"2014","journal-title":"South Med J"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.01.005_bib0031","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","article-title":"Comorbidities in patients with gout prior to and following diagnosis: case-control study","volume":"75","author":"Kuo","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2021.01.005_bib0032","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/ard.2007.081604","article-title":"Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans","volume":"67","author":"Singh","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.01.005_bib0033","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"Quality of life and disability in patients with treatment-failure gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.01.005_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PROM.S8310","article-title":"Gout disease-specific quality of life and the association with gout characteristics","volume":"2010","author":"Hirsch","year":"2010","journal-title":"Patient Relat Outcome Meas"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.01.005_bib0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11926-009-0022-4","article-title":"Quality of life and quality of care for patients with gout","volume":"11","author":"Singh","year":"2009","journal-title":"Curr Rheumatol Rep"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2021.01.005_bib0036","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2020-eular.3893","article-title":"Immunomodulation co-therapy with peglticase: database trends 2014\u20132019 [abstract]","volume":"79","author":"LaMoreaux","year":"2020","journal-title":"Ann Rhuem Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.01.005_bib0037","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res Ther"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722100007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722100007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:03:43Z","timestamp":1758733423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722100007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S004901722100007X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.01.005","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}